| Revenue | DKK 303K | -2243% |
| EBITDA | DKK -281K | -1891% |
| Net profit | DKK -217K | -1849% |
| Total assets | DKK 732K | -35% |
| Equity | DKK 422K | -57% |
| Employees | 3 | — |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | -7 | -25 | -29 | -65 | -14 | 303 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -395 |
| EBITDA | -7 | -25 | -29 | -65 | -14 | -281 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -7 | -25 | -29 | -65 | -14 | -281 |
| Net financials | 0 | -1 | -1 | -1 | -0 | -1 |
| Profit before tax | -7 | -26 | -29 | -66 | -14 | -282 |
| Tax | -0 | 0 | -0 | -21 | -3 | -65 |
| Net profit | -6 | -26 | -29 | -46 | -11 | -217 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 54 | 270 | 261 | 995 | 1.118 | 732 |
| Equity | 44 | 18 | -12 | 995 | 983 | 422 |
| Long-term debt | 0 | 0 | 272 | 0 | 0 | 0 |
| Short-term debt | 10 | 252 | 0 | 0 | 135 | 309 |
| Total debt | 10 | 252 | 272 | 0 | 135 | 309 |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HE Management | Management | 2024 | — | — |
EB Management | Management | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
UniBio Tech Science ApS | Company | 66.7% | 66.7% | 2025 |
Kompany 42 ApS | Company | 25.0% | 25.0% | 2025 |
| Person | Role here | Other companies |
|---|---|---|
| Hans Eibe Sørensen | Management | 0 companies |
| Ebbe Bjerne Busch Larsen | Management | 0 companies |
| Christen Jensen Sørensen | Chairman | 0 companies |
| Martin Grøftehauge | Board of Directors | 0 companies |
| Henrik Busch-Larsen | Board of Directors | 0 companies |
| Birgit Fuglsang Larsen | Board of Directors | 0 companies |